DEFM14A: Yield10 Bioscience to Sell Assets to Nuseed, Plans Liquidation and Dissolution

Yield10 Bioscience is set to sell substantially all of its assets to Nuseed Nutritional US Inc. and subsequently liquidate and dissolve the company, pending stockholder approval.

Summary

• Yield10 Bioscience intends to sell substantially all of its assets to Nuseed Nutritional US Inc. for $5.00 million, less outstanding loan amounts and assumed liabilities.
• Following the asset sale, Yield10 plans to liquidate and dissolve the company, distributing any remaining assets to stockholders.
• A special meeting of stockholders is scheduled for November 8, 2024, to vote on the asset sale, liquidation, and related proposals.
• The company estimates an initial liquidating distribution to stockholders could range from zero to $0.27 million, or $0.39 per share, based on current estimates.
• The board of directors unanimously recommends that stockholders vote in favor of the asset sale and dissolution.
• The company has been working with investment banking firms to assist in reviewing and evaluating a range of financing vehicles to raise capital during calendar year 2023 through July 2024, and despite these efforts, we have been unsuccessful in identifying and completing a strategic transaction, including a merger, reverse merger, strategic partnership or other business combination, other than the Asset Sale, that would have a reasonable likelihood of providing value to our stockholders in excess of the amount our stockholders would receive in a liquidation.

Sentiment

Score: 3

Explanation: The document indicates a negative outcome for the company, with asset sale and dissolution plans suggesting financial distress and limited returns for investors.

Positives

• The asset sale provides some return to investors, which is better than the alternative of ceasing operations.
• The liquidation allows the company to reduce material costs associated with operating as a publicly traded company.
• The company has been working with investment banking firms to assist in reviewing and evaluating a range of financing vehicles to raise capital during calendar year 2023 through July 2024, and despite these efforts, we have been unsuccessful in identifying and completing a strategic transaction, including a merger, reverse merger, strategic partnership or other business combination, other than the Asset Sale, that would have a reasonable likelihood of providing value to our stockholders in excess of the amount our stockholders would receive in a liquidation.

Negatives

• The estimated liquidating distribution to stockholders may be minimal or zero.
• Stockholders may not be able to recognize a loss for U.S. federal income tax purposes until they receive a final distribution.
• The company will incur significant expenses in connection with the asset sale, regardless of whether it is completed.
• The company did not receive a fairness opinion in connection with the asset sale.
• The company is actively winding down its operations.

Risks

• The asset sale is subject to various closing conditions, and there is no guarantee it will be completed.
• The amount distributed to stockholders may be minimal due to expenses and liabilities.
• Stockholders could be held liable for the company's debts if the contingency reserve is inadequate.
• The company may be subject to securities litigation, which could be expensive and divert attention.
• The payment of liquidating distributions, if any, to our stockholders could be delayed.

Future Outlook

The company will liquidate and dissolve following the asset sale, distributing any remaining assets to stockholders. The timing and amount of any liquidating distributions are uncertain.

Management Comments

• OLIVER P. PEOPLESPresident and Chief Executive Officer, and a Member of the Board of Directors: Thank you for your continued support of Yield10 Bioscience, Inc.

Industry Context

This announcement reflects a trend of smaller agricultural bioscience companies facing challenges in securing funding and opting for asset sales and dissolution.

Comparison to Industry Standards

• It's difficult to compare Yield10's situation directly to industry standards due to its unique focus on Camelina and omega-3 oil production.
• However, similar companies in the agricultural biotech space, such as Ceres, Inc., have also faced financial difficulties and strategic shifts.
• The decision to sell assets and dissolve is a common outcome for companies unable to achieve commercial success or secure additional funding, as seen with companies like Synthetic Genomics in the past.

Stakeholder Impact

• Stockholders will receive a liquidating distribution, the amount of which is currently uncertain.
• Employees will likely be terminated as the company winds down its operations.
• Customers and suppliers will need to transition to new relationships with Nuseed or other companies.

Next Steps

• Stockholders will vote on the asset sale, liquidation, and related proposals at the special meeting on November 8, 2024.
• If approved, the company will proceed with the asset sale to Nuseed and subsequently liquidate and dissolve.
• The company will distribute any remaining assets to stockholders after satisfying its liabilities and obligations.

Key Dates

Keywords

liquidation, asset sale, dissolution, Nuseed, Yield10, stockholders, Camelina, Bioscience